Baird Medical Engages with Healthcare Leaders Amid 2025 J.P. Morgan Healthcare Conference
Baird Medical (NASDAQ: BDMD), a leader in minimally invasive Microwave Ablation (MWA) technology, participated in activities surrounding the 2025 J.P. Morgan Healthcare Conference in San Francisco. Following its Nasdaq debut in October 2024, the company engaged with healthcare investors and industry leaders, discussing advancements in microwave ablation technology and patient outcomes.
Chairwoman Haimei Wu highlighted the conference's importance in connecting with shareholders, innovators, and healthcare sector advisors. The company plans to utilize these interactions to support its 2025 strategic initiatives, focusing on expanding its U.S. presence and strengthening collaborations with key opinion leaders (KOLs) in medical technology.
Baird Medical (NASDAQ: BDMD), un leader nella tecnologia di Ablazione a Microonde (MWA) minimamente invasiva, ha partecipato alle attività legate alla 2025 J.P. Morgan Healthcare Conference a San Francisco. Dopo il suo debutto al Nasdaq nell'ottobre 2024, l'azienda ha interagito con investitori nel settore sanitario e leader del settore, discutendo i progressi nella tecnologia di ablazione a microonde e i risultati per i pazienti.
La presidente Haimei Wu ha sottolineato l'importanza della conferenza nel connettersi con azionisti, innovatori e consulenti del settore sanitario. L'azienda prevede di utilizzare queste interazioni per supportare le sue iniziative strategiche del 2025, concentrandosi sull'espansione della sua presenza negli Stati Uniti e sul rafforzamento delle collaborazioni con i key opinion leaders (KOL) nella tecnologia medica.
Baird Medical (NASDAQ: BDMD), un líder en tecnología de Ablación por Microondas (MWA) mínimamente invasiva, participó en actividades en torno a la 2025 J.P. Morgan Healthcare Conference en San Francisco. Tras su debuto en Nasdaq en octubre de 2024, la compañía interactuó con inversores en el sector salud y líderes de la industria, discutiendo los avances en la tecnología de ablación por microondas y los resultados para los pacientes.
La presidenta Haimei Wu destacó la importancia de la conferencia para conectar con accionistas, innovadores y asesores del sector salud. La empresa planea utilizar estas interacciones para apoyar sus iniciativas estratégicas de 2025, enfocándose en expandir su presencia en EE. UU. y fortalecer colaboraciones con líderes de opinión clave (KOL) en tecnología médica.
Baird Medical (NASDAQ: BDMD), 최소 침습 마이크로웨이브 절제술 (MWA) 기술의 선두주자로서, 샌프란시스코에서 열린 2025 J.P. Morgan Healthcare Conference와 관련된 활동에 참여했습니다. 2024년 10월 Nasdaq에 상장한 이후, 회사는 의료 투자자 및 업계 리더들과의 소통을 통해 마이크로웨이브 절제술 기술의 발전과 환자 결과에 대해 논의했습니다.
회장 Haimei Wu는 주주, 혁신가 및 의료 분야 자문가와의 연결에서 이 회의의 중요성을 강조했습니다. 회사는 이러한 상호작용을 활용하여 2025년 전략적 이니셔티브를 지원할 계획이며, 미국 내 존재감을 확장하고 의료 기술 분야의 주요 의견 리더(KOL)와의 협력을 강화하는 데 중점을 둘 것입니다.
Baird Medical (NASDAQ: BDMD), un leader dans la technologie d'Ablation par Micro-ondes (MWA) minimale invasive, a participé à des activités entourant la 2025 J.P. Morgan Healthcare Conference à San Francisco. Suite à son début sur le Nasdaq en octobre 2024, l'entreprise a échangé avec des investisseurs dans le secteur de la santé et des leaders de l'industrie, discutant des avancées dans la technologie d'ablation par micro-ondes et des résultats pour les patients.
La présidente Haimei Wu a souligné l'importance de la conférence pour établir des liens avec les actionnaires, les innovateurs et les conseillers du secteur de la santé. L'entreprise prévoit d'utiliser ces interactions pour soutenir ses initiatives stratégiques de 2025, en se concentrant sur l'expansion de sa présence aux États-Unis et le renforcement de collaborations avec les leaders d'opinion clés (KOL) dans la technologie médicale.
Baird Medical (NASDAQ: BDMD), ein führendes Unternehmen in der minimal-invasiven Mikrowellenablation (MWA) Technologie, nahm an Aktivitäten im Rahmen der 2025 J.P. Morgan Healthcare Conference in San Francisco teil. Nach seinem Nasdaq-Debüt im Oktober 2024 war das Unternehmen im Austausch mit Investoren im Gesundheitswesen und Branchenführern, um Fortschritte in der Mikrowellenablationstechnologie und die Patientenergebnisse zu diskutieren.
Vorsitzende Haimei Wu betonte die Bedeutung der Konferenz für die Verbindung mit Aktionären, Innovatoren und Beratern des Gesundheitssektors. Das Unternehmen plant, diese Interaktionen zu nutzen, um seine strategischen Initiativen für 2025 zu unterstützen, mit einem Fokus auf die Erweiterung seiner Präsenz in den USA und die Stärkung von Kooperationen mit wichtigen Meinungsführern (KOLs) in der Medizintechnologie.
- None.
- None.
Following its successful debut on Nasdaq in October 2024, Baird Medical connected with healthcare investors and industry leaders during the week of the conference, engaging in meaningful discussions on the company's advancements in microwave ablation technology and its commitment to improving patient outcomes.
"Being in
Looking ahead, Baird Medical remains committed to leveraging the insights and relationships gained from these interactions to drive its 2025 strategic initiatives. The company will continue expanding its
About Baird Medical
Baird Medical is a leading provider of minimally invasive microwave ablation (MWA) technology, offering advanced treatment solutions for conditions such as thyroid nodules, breast disease, uterine fibroids, and liver cancer. A publicly traded company on NASDAQ, Baird Medical is dedicated to enhancing patient care through precision, efficiency, and safety in its innovative medical devices. For more information, please visit https://bairdmed.com/
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts and generally relate to future events or Baird Medical's future financial or operational performance. In some cases, you can identify forward-looking statements by terminology such as "may," "might," "will," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue," or the negative of these terms or other similar expressions.
These forward-looking statements are subject to risks, uncertainties, and assumptions that could cause actual results or outcomes to differ materially from those expressed or implied. These statements are based on estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. Risks and uncertainties may emerge over time, and it is not possible to anticipate all potential factors that could affect Baird Medical's business and financial performance.
Factors that could cause actual results to differ materially include, but are not limited to: (1) the risk that Baird Medical may not achieve its expansion goals in
Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Baird Medical undertakes no obligation to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.
View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-engages-with-healthcare-leaders-amid-2025-jp-morgan-healthcare-conference-302353999.html
SOURCE BDMD
FAQ
When did Baird Medical (BDMD) go public on NASDAQ?
What is Baird Medical's (BDMD) main technology focus?
What are Baird Medical's (BDMD) strategic plans for 2025?
Who is the Chairwoman of Baird Medical (BDMD)?
